GSK press releases Follow https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-for-long-acting-cabotegravir-and-rilpivirine-for-the-treatment-of-hiv-showing-continued-virologic-suppression-to-96-weeks/ gsk.com
